Posted by Michael Wonder on 11 Sep 2020
Health Canada approves Tremfya (guselkumab injection), a first in class, selective interleukin 23 inhibitor for active psoriatic arthritis
10 September 2020 - Data show Tremfya significantly improved signs and symptoms in joints, skin, and soft tissue of adults with active psoriatic arthritis.
Janssen today announced that Health Canada has approved Tremfya (guselkumab injection) for adult patients with active psoriatic arthritis, a chronic progressive disease characterised by painful joints and skin inflammation. Tremfya can be used alone or in combination with a conventional disease-modifying anti-rheumatic drug, such as methotrexate.
This approval for Tremfya is based on results from two pivotal Phase 3 clinical trials; DISCOVER-1 and DISCOVER-2, which evaluated the efficacy and safety of Tremfya, administered by subcutaneous injection in adults with active psoriatic arthritis compared to a placebo.
